Patents by Inventor David V. Schaffer

David V. Schaffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220228129
    Abstract: The present disclosure provides an in vitro mammalian cell that is genetically modified to provide for enhanced production of adeno-associated virus (AAV) virions. The mammalian cells can be used to produce AAV virions, e.g., recombinant AAV virions that include a heterologous nucleic acid encoding a gene product; the present disclosure thus provides methods for producing an AAV virion, which may be a recombinant AAV virion.
    Type: Application
    Filed: April 22, 2020
    Publication date: July 21, 2022
    Inventors: David V. Schaffer, Christopher Barnes, David Stephen Ojala
  • Publication number: 20220195371
    Abstract: Provided are systems and methods for spatially and temporally controlling light with an illumination device comprising a light source operably connected to a circuit board, one or more light guide plates, one or more optical masks, a controller, and a computer readable medium, comprising instructions that, when executed by the controller, cause the controller to: illuminate a cell or a substrate with light from the light source, and spatially and temporally control illumination of light to the cell or the substrate with one or more illumination parameters, wherein the one or more light guide plates provides uniform illumination of the light. Also provided herein are methods of screening using the system and/or device of the present disclosure.
    Type: Application
    Filed: February 10, 2022
    Publication date: June 23, 2022
    Inventors: David V. Schaffer, Nicole Anne Repina, Ruoxing Lei, Thomas Patrick C. McClave
  • Patent number: 11291707
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: April 5, 2022
    Assignee: The Regents of the University of California
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20220017876
    Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Application
    Filed: September 7, 2021
    Publication date: January 20, 2022
    Inventors: David V. Schaffer, Melissa A. Kotterman, Bum-Yeol Hwang, James T. Koerber
  • Patent number: 11136557
    Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Melissa A. Kotterman, Bum-Yeol Hwang, James T. Koerber
  • Publication number: 20210285009
    Abstract: The present disclosure provides a gene delivery system comprising: a) an R2 retrotransposon R2 polypeptide, or a first nucleic acid comprising a nucleotide sequence encoding the R2 polypeptide; and b) a nucleic acid comprising a heterologous nucleotide sequence encoding one or more heterologous gene products, where the heterologous nucleotide sequence is flanked by an R2 retrotransposon 3? untranslated region (UTR) and an R2 retrotransposon 5? UTR, and where the heterologous nucleotide sequence has a length of at least 200 nucleotides. The present disclosure provides a method of delivering one or more gene products of interest to a eukaryotic cell, the method comprising contacting the cell with the gene delivery vehicle system.
    Type: Application
    Filed: July 11, 2019
    Publication date: September 16, 2021
    Inventors: David V. Schaffer, Christopher Barnes
  • Publication number: 20210283274
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: July 27, 2017
    Publication date: September 16, 2021
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • Patent number: 11111375
    Abstract: The present disclosure provides a three-dimensional culture system comprising a biocompatible polymer and a combination of factors in an amount effective to induce differentiation of oligodendrocyte precursors and/or oligodendrocytes from pluripotent stem cells. The present disclosure provides methods of generating oligodendrocyte precursors and/or oligodendrocytes using a three-dimensional culture system of the present disclosure. The present disclosure provides methods to treat neurological diseases and demyelinating diseases.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: September 7, 2021
    Assignee: The Regents of the University of California
    Inventors: Gonçalo Rodrigues, David V. Schaffer
  • Publication number: 20210147876
    Abstract: The present disclosure provides recombinant adeno-associated virus (rAAV) virions comprising a variant AAV capsid protein, e.g., an AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence. An rAAV virion of the present disclosure can exhibit greater infectivity of a target cell. The present disclosure also provides methods of delivering a gene product to a target cell in an individual by administering to the individual an rAAV of the present disclosure. The present disclosure also provides methods of generating rAAV virions that have a variant AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence.
    Type: Application
    Filed: November 30, 2020
    Publication date: May 20, 2021
    Inventors: David S. Ojala, Jorge Santiago-Ortiz, Oscar Westesson, David V. Schaffer, Ian H. Holmes, John Weinstein
  • Publication number: 20210113655
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Application
    Filed: September 1, 2020
    Publication date: April 22, 2021
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Publication number: 20210113702
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Application
    Filed: August 5, 2020
    Publication date: April 22, 2021
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Patent number: 10982055
    Abstract: The present disclosure provides thermoreversible polymers, hydrogel compositions comprising the thermoreversible polymers, as well as methods of making and using the thermoreversible polymers.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 20, 2021
    Assignee: The Regents of the University of California
    Inventors: Christina Marie Fuentes, Barbara L. Ekerdt, David V. Schaffer, Rachel Segalman, Yuguo Lei
  • Publication number: 20210077552
    Abstract: The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 18, 2021
    Inventors: David V. Schaffer, Brian Kaspar, Narendra Maheshri
  • Patent number: 10883117
    Abstract: The present disclosure provides recombinant adeno-associated virus (rAAV) virions comprising a variant AAV capsid protein, e.g., an AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence. An rAAV virion of the present disclosure can exhibit greater infectivity of a target cell. The present disclosure also provides methods of delivering a gene product to a target cell in an individual by administering to the individual an rAAV of the present disclosure. The present disclosure also provides methods of generating rAAV virions that have a variant AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 5, 2021
    Assignee: The Regents of the University of California
    Inventors: David S. Ojala, Jorge Santiago-Ortiz, Oscar Westesson, David V. Schaffer, Ian H. Holmes, John Weinstein
  • Patent number: 10765759
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson
  • Publication number: 20200231942
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: October 24, 2019
    Publication date: July 23, 2020
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery
  • Publication number: 20200149064
    Abstract: Disclosed herein is a functional nucleic acid that includes i) one or more coding nucleotide sequences encoding a genome editing endonuclease; ii) regulatory sequences operably linked to the one or more coding nucleotide sequences; and iii) one or more genome editing endonuclease-recognized sequences, wherein the functional nucleic acid is configured to express the endonuclease in a host cell and thereby provide a cellular endonuclease activity in a sequence-specific manner in the host cell, and wherein cleavage of the functional nucleic acid by the endonuclease inactivates the cellular endonuclease activity. Methods of using the present functional nucleic acid, and systems and kits that find use in performing the same are also provided.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 14, 2020
    Inventors: David V. Schaffer, Benjamin Ezra Epstein
  • Publication number: 20200121746
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Inventors: David V. Schaffer, Leah C. Byrne, Timothy P. Day, John G. Flannery
  • Publication number: 20200095559
    Abstract: The present disclosure provides recombinant adeno-associated virus virions with variant capsid protein, where the recombinant AAV (rAAV) virions exhibit one or more of increased ability to cross neuronal cell barriers, increased infectivity of a neural stem cell, increased infectivity of a neuronal cell, and reduced susceptibility to antibody neutralization, compared to a control AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a neural stem cell or a neuronal cell in an individual. The present disclosure also provides methods of modifying a target nucleic acid present in a neural stem cell or neuronal cell.
    Type: Application
    Filed: August 22, 2018
    Publication date: March 26, 2020
    Inventors: David V. Schaffer, David Stephen Ojala, Philip A. Romero